- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04011397
Feasibility of REHIT in NDH Patients
Feasibility of Procedures for a Pragmatic Randomized Controlled Trial of Reduced Exertion, High-intensity Interval Training (REHIT) With Non-diabetic Hyperglycaemia Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background Physical activity and exercise interventions to improve health frequently bring about intended effects under ideal circumstances but fail to demonstrate effectiveness when translated to demonstrable benefits in real-world contexts. The aim of this feasibility study was to describe and report data relevant to the acceptability of an exercise intervention (reduced-exertion, high-intensity interval training) in non-diabetic hyperglycaemia (NDH) patients delivered in a National Health Service (NHS) setting.
Individuals with NDH are an intermediary group of patients whose blood glucose levels are higher than normal but not high enough to be diagnosed as diabetic. Such hyperglycaemic blood glucose excursions in 'pre-diabetic' states contribute to the development of macro- and micro-vascular disease risk and increases the risk of developing overt type 2 diabetes. Interventions - such as increased physical activity - for individuals who are diagnostically considered to have NDH are high priority, as they provide a substantial opportunity for preventing future burden of diabetes on patients, the NHS, and the economy.
Evidence supporting the efficacy of exercise and physical activity as preventative or therapeutic treatments for a range of chronic diseases, including obesity and diabetes, is incontrovertible. However, exercise adherence is considered a significant issue. The most commonly cited barrier to undertaking physical activity is perceived 'lack of time'. Consequently, there has been a recent interest in high-intensity interval training (HIT) which is characterised by brief periods of repeated very high-intensity exercise interspersed with longer periods of recovery. More recently attempts have been made to modify HIT to make it more time-efficient and tolerable. This approach is known as reduced-exertion, high-intensity interval training (REHIT). In this study, issues of acceptability and feasibility were considered when implementing a REHIT intervention into usual care within an NHS setting.
Methods The purpose was to assess whether it would be appropriate to progress to a larger-scale pragmatic trial, and to optimise the design and conduct of any such trial. The intention was to recruit 40 participants from a single centre (specialist diabesity centre). Patients were eligible to take part if they were diagnostically defined as non-diabetic hyperglycaemic based on a glycated haemoglobin value of 42-46 mmol·mol. Methodological issues were used to analyse problems that arose.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Accessing the NHS Trust Weight Management Service (Specialist Diabesity Clinic)
- Aged between 18 and 65 years (inclusive)
- Diagnosed as NDH (using standard criteria)
- Male or female
- Any ethnicity
- Not currently partaking in a new structured exercise intervention
- Considered low or medium risk for exercise using standard risk stratification [37]
Exclusion Criteria:
- < 18 years and ≥ 66 years
- Currently partaking in a new structured exercise intervention
- Euglycaemic
- Diagnosed with type 1 or type 2 diabetes; taking insulin; history of end stage liver or kidney disease, neuropathy or retinopathy; has hypertension that cannot be controlled by standard medication; has cardiovascular disease, or another contraindication to exercise
- Considered high risk for exercise using standard risk stratification [37]
- Unable to adequately understand verbal explanations and written information given in English (there were no funds available for translation services)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention group
Exercise intervention (reduced-exertion, high-intensity interval training) alongside normal treatment.
[low recruitment prohibited control arm]
|
Exercise intervention (reduced-exertion, high-intensity interval training) delivered within an NHS setting.
Consisted 10 min of cycle ergometry (inclusive of warm-up and cool down) including very brief maximal cycle sprints.
Members of a multi-disciplinary team including a consultant, diabetes specialist nurse, clinical psychologist, physiotherapist, and dietician worked together to promote patient self-management.
Care was tailored to the specific circumstances of each patient after initial assessment and focussed on weight management, dietary education, behavioural therapy, and supported pharmacotherapy initiation as appropriate.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients screened and considered eligible to take part in the study
Time Frame: 4-weeks
|
Defined as the number of patients who had contact with the recruitment team and who were assessed for eligibility using inclusion and exclusion criteria.
|
4-weeks
|
|
Reporting of adverse events
Time Frame: From first exposure to intervention to last (approx. 6-weeks)
|
An adverse event was defined as any untoward occurrence that happened during the conduct of the study.
|
From first exposure to intervention to last (approx. 6-weeks)
|
|
Intervention adherence
Time Frame: From first exposure to intervention to last (approx. 6-weeks)
|
Intervention adherence was calculated by summing the total number of participants and the target number of REHIT sessions (15 per participant) and comparing this against the actual completed sessions.
|
From first exposure to intervention to last (approx. 6-weeks)
|
|
Change in affective valence (pleasure-displeasure)
Time Frame: Change from first exposure to intervention to last (approx. 6 weeks)
|
Pre-validated 'Feeling Scale' questionnaire which measure pleasure/displeasure responses during exercise.
This is a single-item, 11-point, bipolar scale and ranges from - 5 'very bad' to + 5 'very good', with anchors designated for 0 (neutral) and all odd integers in-between.
Lower scores are considered to be a worse outcome.
|
Change from first exposure to intervention to last (approx. 6 weeks)
|
|
Change in perceived exertion
Time Frame: Change from first exposure to intervention to last (approx. 6 weeks)
|
Pre-validated 'Rating of Perceived Exertion' questionnaire which measures perceived effort during exercise.
This is a 15-point scale and ranges from 6 'no exertion' to 20 'maximal exertion' with anchors designated for all the odd integers in-between.
A higher score is considered a worse outcome.
|
Change from first exposure to intervention to last (approx. 6 weeks)
|
|
Change in enjoyment
Time Frame: Change from first exposure to intervention to last (approx. 6 weeks)
|
Pre-validated 'Exercise Enjoyment Scale' (ESS) which measures enjoyment associated with exercise.
This is a single-item, 7-point scale.
Anchors are given at every integer, ranging from 1 'not at all' to 7 'extremely'.
A lower score is a worse outcome.
|
Change from first exposure to intervention to last (approx. 6 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in peak oxygen uptake (fitness test)
Time Frame: Change from baseline peak oxygen uptake at approx. 6-weeks
|
Progressive cycle test to measure cardiovascular fitness (using gas analysis)
|
Change from baseline peak oxygen uptake at approx. 6-weeks
|
|
Change in HBA1c (blood test)
Time Frame: Change from baseline HbA1c at approx. 6-weeks
|
Widely used measure of blood glucose control
|
Change from baseline HbA1c at approx. 6-weeks
|
|
Change in body composition
Time Frame: Change from baseline body composition at approx. 6-weeks
|
Fat mass and fat-free mass estimated via bioelectrical impedance analysis
|
Change from baseline body composition at approx. 6-weeks
|
|
Change in systolic and diastolic blood pressure
Time Frame: Change from baseline systolic and diastolic blood pressure at approx. 6-weeks
|
Measured via automated digital blood pressure monitor
|
Change from baseline systolic and diastolic blood pressure at approx. 6-weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Matthew Haines, University of Huddersfield
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- UHuddersfield
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of North Carolina, Chapel HillAmerican Diabetes AssociationNot yet recruitingType 2 Diabetes Mellitus (T2DM) | Diabetes (DM) | Insulin Dependent Diabetes | Type 1 Diabetes (T1D) | Diabetes Education | Diabetes Care | Diabetes (Insulin-requiring, Type 1 or Type 2)United States
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
Steno Diabetes Center CopenhagenNot yet recruitingDiabetes | Diabetes Type 1 | Diabetes Type 2 | Digital Health | Diabetes Care | Remote Patient MonitoringDenmark
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
COUR Pharmaceutical Development Company, Inc.RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)United States
Clinical Trials on Exercise intervention
-
VA Office of Research and DevelopmentRecruitingMobility Impairment | Asymptomatic Carotid Stenosis (50-69%)United States
-
The Miriam HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of AarhusRecruiting
-
Glasgow Caledonian UniversityUnknown
-
Turku University HospitalUniversity of Turku; University of Helsinki; Academy of Finland; European Foundation... and other collaboratorsUnknownType 2 Diabetes Mellitus | Healthy VolunteersFinland
-
Hacettepe UniversityHacettepe University Scientific Research Projects Coordination UnitNot yet recruitingSubstrate Oxidation | Postprandial Metabolism | Exercise Physiology | Cardiovascular Risk MarkersTurkey (Türkiye)
-
Medipol UniversityCompleted
-
University Medical Center GroningenDutch Kidney Foundation; Innovation Fund of the Dutch Medical Insurance CompaniesCompletedMetabolic Syndrome | Kidney Transplant | Post-transplant Weight GainNetherlands
-
Istanbul UniversityCompletedGlenohumeral ArthritisTurkey
-
Aristotle University Of ThessalonikiCompleted